Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 09/30 10:00:01 pm
79.12 USD   +1.62%
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Ye..
09/27 NASDAQ 100 MOVE : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Sciences : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/29/2016 | 05:56pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- Gilead Sciences, Inc. (Nasdaq:GILD) announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active ulcerative colitis. This decision follows a planned interim analysis of unblinded efficacy and safety data by the Data Monitoring Committee (DMC) after the first 150 patients of a planned 1600-patient trial were treated for an 8-week induction duration. The DMC recommended that the study be terminated early due to meeting the pre-specified futility and efficacy criteria. No safety concerns were noted in this interim analysis. Gilead has also reviewed the data and determined that there is insufficient evidence of a treatment benefit in the group of patients randomized to receive either one of two doses of GS-5745 (see also Pharmaceutical Companies).

Separately, a Phase 3 study of GS-5745 is ongoing in patients with gastric cancer, as well as a Phase 2 study in patients with gastric cancer in combination with nivolumab and additional Phase 2 studies in moderately to severely active Crohn's disease, rheumatoid arthritis and cystic fibrosis. These studies will continue as planned. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from other clinical trials for GS-5745. In addition, it is possible that Gilead may make a strategic decision to discontinue development of GS-5745 if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, GS-5745 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. View source version on businesswire.com: http://www.businesswire.com/news/home/20160921006487/en/

Keywords for this news article include: Pharmaceutical Companies, Gastroenteritis, Colonic Diseases, Gastroenterology, Ulcerative Colitis, Gilead Sciences Inc., Digestive System Diseases, Gastrointestinal Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
09/29 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Year Visceral ..
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
09/21 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Creation of a ..
09/20 STOCKS HIGHLIGHTS : Gilead Sciences, Inc. Wellcare Health Plans, Inc.
09/16 GILEAD SCIENCES : Prices $5 Billion of Senior Unsecured Notes
09/15 GILEAD SCIENCES : to Present at Three Upcoming Investor Conferences in September
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/29 NONALCOHOLIC STEATOHEPATITIS (NASH) : What's The Market Opportunity And Who Are ..
09/29 Yellen And Clinton Combo To Take Market Higher
09/28 VALEANT : Is Bankruptcy Possible?
09/27 My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/27 Allergan Validates Gilead Sciences NASH Pipeline
Advertisement
Financials ($)
Sales 2016 30 469 M
EBIT 2016 20 160 M
Net income 2016 14 539 M
Debt 2016 5 504 M
Yield 2016 2,38%
P/E ratio 2016 7,33
P/E ratio 2017 7,01
EV / Sales 2016 3,55x
EV / Sales 2017 3,52x
Capitalization 102 749 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-23.06%102 749
AMGEN, INC.1.92%123 816
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
ACTELION LTD21.70%18 780
More Results